Lilly's Lebanon API Plant Wins a Federal Fast-Track

The FDA named Eli Lilly's Lebanon API plant in Boone County one of seven inaugural participants in its PreCheck Pilot Program on June 29, an initiative that reviews facilities during construction and can save up to 14 months of regulatory timeline. The plant manufactures active pharmaceutical ingredients for Zepbound, Mounjaro, and Foundayo. Novo Nordisk, Lilly's primary GLP-1 competitor, is structurally ineligible for PreCheck because the program excludes facility expansions, Novo's domestic buildout relies on expanding existing sites. For Indiana suppliers in precision components, packaging, and facility services, the procurement qualification window just compressed. Get into Lilly's vendor process now, not after FDA clearance lands.